Mary Anne Heino net worth and biography

Mary Heino Biography and Net Worth

CEO of Lantheus
Mary Anne Heino brings to Lantheus 30 years of diverse pharmaceutical industry experience. Joining Lantheus in April 2013 as Chief Commercial Officer, Ms. Heino was promoted to Chief Operating Officer in March 2015 and to President and Chief Executive Officer in August 2015. Prior to joining Lantheus, Ms. Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of World Wide Sales and Marketing.  Before that, Ms. Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson Company, including Vice President Strategic Planning and Competitive Intelligence, Vice President Sales, Executive Director Customer Relationship Management and Senior Director Immunology Marketing. Ms. Heino began her professional career with Janssen Pharmaceutica N.V. as a Sales Representative in June 1989 and worked her way up to the role of Field Sales Director in 1999. Ms. Heino received her Master’s in Business Administration from the Stern School of Business at New York University. She earned a Bachelor’s of Science in Nursing from the City University of New York and a Bachelor’s of Science in Biology from the State University of New York at Stony Brook. She is currently on the Board of Directors for MassMEDIC, an industry association that serves the MedTech community of Massachusetts, and serves on the Executive Committee for the Massachusetts Business Roundtable (MBR).

What is Mary Anne Heino's net worth?

The estimated net worth of Mary Anne Heino is at least $47.96 million as of May 9th, 2022. Ms. Heino owns 695,115 shares of Lantheus stock worth more than $47,962,935 as of September 29th. This net worth evaluation does not reflect any other investments that Ms. Heino may own. Additionally, Ms. Heino receives an annual salary of $2,150,000.00 as CEO at Lantheus. Learn More about Mary Anne Heino's net worth.

How old is Mary Anne Heino?

Ms. Heino is currently 62 years old. There are 7 older executives and no younger executives at Lantheus. Learn More on Mary Anne Heino's age.

What is Mary Anne Heino's salary?

As the CEO of Lantheus Holdings, Inc., Ms. Heino earned a total compensation package of $6,185,143.00 in 2021. Ms. Heino earned a salary of $796,773.00, stock awards of $4,036,516.00, non-equity compensation of $1,332,355.00, and other compensation of $19,500.00. Learn More on Mary Anne Heino's salary.

How do I contact Mary Anne Heino?

The corporate mailing address for Ms. Heino and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected] Learn More on Mary Anne Heino's contact information.

Has Mary Anne Heino been buying or selling shares of Lantheus?

Mary Anne Heino has not been actively trading shares of Lantheus during the last quarter. Most recently, Mary Anne Heino sold 12,276 shares of the business's stock in a transaction on Monday, May 9th. The shares were sold at an average price of $61.19, for a transaction totalling $751,168.44. Following the completion of the sale, the chief executive officer now directly owns 695,115 shares of the company's stock, valued at $42,534,086.85. Learn More on Mary Anne Heino's trading history.

Who are Lantheus' active insiders?

Lantheus' insider roster includes Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.

Are insiders buying or selling shares of Lantheus?

During the last year, insiders at the medical equipment provider sold shares 30 times. They sold a total of 212,667 shares worth more than $12,092,243.05. The most recent insider tranaction occured on September, 15th when CAO Andrea Sabens sold 386 shares worth more than $33,130.38. Insiders at Lantheus own 1.6 % of the company. Learn More about insider trades at Lantheus.

Information on this page was last updated on 9/15/2022.

Mary Anne Heino Insider Trading History at Lantheus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2022Sell12,276$61.19$751,168.44695,115View SEC Filing Icon  
3/3/2022Sell11,173$52.13$582,448.49View SEC Filing Icon  
2/28/2022Sell43,909$46.50$2,041,768.50View SEC Filing Icon  
11/10/2021Sell13,333$30.12$401,589.96View SEC Filing Icon  
4/12/2021Sell19,421$20.66$401,237.86View SEC Filing Icon  
3/5/2021Sell27,157$18.26$495,886.82711,720View SEC Filing Icon  
7/23/2020Sell3,000$16.02$48,060.00604,793View SEC Filing Icon  
7/15/2020Sell22,125$16.01$354,221.25607,793View SEC Filing Icon  
4/27/2020Sell30,033$13.77$413,554.41634,318View SEC Filing Icon  
2/26/2020Sell6,615$17.09$113,050.35549,399View SEC Filing Icon  
2/24/2020Sell9,898$16.06$158,961.88556,014View SEC Filing Icon  
12/20/2019Sell19,260$20.85$401,571.00563,034View SEC Filing Icon  
9/20/2019Sell15,590$25.81$402,377.90582,294View SEC Filing Icon  
9/3/2019Sell25,538$21.21$541,660.98597,884View SEC Filing Icon  
6/20/2019Sell14,340$27.89$399,942.60624,997View SEC Filing Icon  
5/20/2019Sell16,827$23.89$401,997.03637,762View SEC Filing Icon  
4/26/2019Sell29,813$24.86$741,151.18654,589View SEC Filing Icon  
4/12/2019Sell15,799$25.40$401,294.60684,402View SEC Filing Icon  
3/5/2019Sell9,294$23.35$217,014.90709,220View SEC Filing Icon  
2/25/2019Sell9,456$24.06$227,511.36621,326View SEC Filing Icon  
1/30/2019Sell9,564$16.47$157,519.08630,782View SEC Filing Icon  
7/12/2017Sell10,000$18.05$180,500.00592,468View SEC Filing Icon  
6/12/2017Sell10,000$15.39$153,900.00602,468View SEC Filing Icon  
See Full Table

Mary Anne Heino Buying and Selling Activity at Lantheus

This chart shows Mary Anne Heino's buying and selling at Lantheus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lantheus Company Overview

Lantheus logo
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Read More

Today's Range

Now: $69.00
Low: $66.68
High: $69.11

50 Day Range

MA: $78.30
Low: $66.60
High: $86.60

2 Week Range

Now: $69.00
Low: $22.20
High: $87.47

Volume

25,569 shs

Average Volume

865,917 shs

Market Capitalization

$4.74 billion

P/E Ratio

160.47

Dividend Yield

N/A

Beta

0.77